v3.20.2
Acquisition, Equity-Method Investment and Licensing Arrangements - Schedule of Equity-Method Investment (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 27, 2020
Jun. 30, 2020
Sep. 29, 2019
Sep. 27, 2020
Jun. 30, 2020
Sep. 29, 2019
Jun. 28, 2020
Dec. 31, 2019
Jun. 30, 2019
Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]                    
Current assets $ 47,739     $ 47,739       $ 32,803    
Total assets 178,983     178,983       167,489    
Current liabilities 34,154     34,154       37,304    
Total liabilities 113,487     113,487       104,042    
Equity attributable to shareholders 65,259     65,259       63,143    
Equity attributable to noncontrolling interests 236     236       303    
Total equity 65,495   $ 65,396 65,495   $ 65,396 $ 64,564 $ 63,447 $ 59,924 $ 63,758
Income from continuing operations 2,202   7,680 9,046   16,625        
Net income 2,202   7,684 9,046   16,628        
Income attributable to shareholders $ 2,194   $ 7,680 $ 9,022   $ 16,609        
GSK Consumer Healthcare [Member]                    
Schedule of Equity Method Investments [Line Items]                    
Current assets   $ 7,136     $ 7,136          
Noncurrent assets   37,108     37,108          
Total assets   44,244     44,244          
Current liabilities   4,992     4,992          
Noncurrent liabilities   5,195     5,195          
Total liabilities   10,187     10,187          
Equity attributable to shareholders   33,919     33,919          
Equity attributable to noncontrolling interests   138     138          
Total equity   34,057     34,057          
Net sales   2,927     9,618          
Cost of sales   (1,061)     (4,266)          
Gross profit   1,866     5,352          
Income from continuing operations   524     995          
Net income   524     995          
Income attributable to shareholders   $ 518     $ 959